---
title: "AstraZeneca Q2 profit beats estimates as cancer drug sales drive growth"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293899578.md"
description: "AstraZeneca reported Q2 earnings beating estimates, with core EPS rising to $2.63 and revenue reaching $15.38B, driven by strong sales of cancer drugs Enhertu, Imfinzi, and Tagrisso. Despite a disappointing trial for heart disease drug Wainua causing an 8% YTD stock drop, CEO Pascal Soriot reaffirmed FY2026 guidance, expressing confidence in long-term growth and the company's robust pipeline."
datetime: "2026-07-27T08:14:24.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293899578.md)
  - [en](https://longbridge.com/en/news/293899578.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293899578.md)
---

# AstraZeneca Q2 profit beats estimates as cancer drug sales drive growth


### Related Stocks

- [AZN.US](https://longbridge.com/en/quote/AZN.US.md)
- [AZN.UK](https://longbridge.com/en/quote/AZN.UK.md)

## Related News & Research

- [Key facts: AstraZeneca (AZN) merger talks with BMS; 6% revenue rise](https://longbridge.com/en/news/294654032.md)
- [Keymed’s CLDN18.2 Drug CMG901 Delivers Phase III Survival Gain in Gastric Cancer](https://longbridge.com/en/news/294008140.md)
- [Scott Galloway says GLP-1 drugs are a 'silver bullet' for America's woes, if we're not 'stupid enough' to get in the way](https://longbridge.com/en/news/294581321.md)
- [Hamlet Biopharma wins US patent, nears Japan grant for HAMLET drug technology](https://longbridge.com/en/news/294053937.md)
- [CSPC Sees Profit Surge on AstraZeneca Deal and Solid Drug Sales](https://longbridge.com/en/news/293910247.md)